Agouron Pharmaceuticals (AGPH) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Agouron Pharmaceuticals (AGPH)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: R Hamilton who wrote (4227)	5/5/1998 3:39:00 PM
From: David Wise	Read Replies (1) of 6136

REPLIGEN - Teamed with Pfizer; received grant from National Cancer Institute last month for work on anti-angiogenesis compounds. Advantage over others - "since they are readily synthesized organic compounds, they have the potential to be low cost, easily administered alternatives to the protein inhibitors of angiogenesis being developed by many other organizations". This quote is from April 23. RGEN - Only 18,000,000 shares - no analyst following, yet, and trades under $3.00. Looks like a hit for Pfizer, also.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next